Darolutamide in Metastatic Prostate Cancer

Abstract

To the Editor: The results of the ARASENS trial (March 24 issue)¹ represent the beginning of the third revolution in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In this trial, Smith and colleagues found that overall survival was significantly longer with the combination of darolutamide, androgen-deprivation therapy, and docetaxel than with placebo plus androgen-deprivation therapy and docetaxel. However, the trial results raise some crucial questions. One of the most important is the identification of patients who would most benefit from such triplet therapy. In the PEACE-1 trial,² investigators found that the greatest benefit from triplet therapy with abiraterone plus . . .